Sotagliflozin Reprograms Hepatic Lipid Metabolism and Attenuates Atherosclerosis Beyond Empagliflozin in CKM Mice
Keith Louis Saum, Jessica Sim, Lixia Zeng, Charles A. Steward, Pradeep P. Kayampilly, Alethia Dixon, Anand Singh, Ahmed Abdel‐Latif, Subramaniam Pennathur
This study compares sotagliflozin and empagliflozin in CKM mice, finding sotagliflozin more effectively reduces atherosclerosis and metabolic syndrome through hepatic lipid metabolism reprogramming.
bioRxiv · Oct 1, 2026 · PreprintPharmacology & Toxicology